Management of Type 2 Diabetes in Patients With Cardiovascular Risk

Reducing CV Risk Image
Listen as a multidisciplinary expert panel debates optimal management of patients with T2DM and varying degrees of cardiovascular risk.
Zachary T. Bloomgarden, MD, MACE
Program Director
Mikhail N. Kosiborod, MD
Pamela Kushner, MD, FAAFP
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 20, 2018 Expiration: July 19, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Routinely assess patients with T2DM for CV risk factors based on an understanding of the pathophysiology of cardiometabolic syndrome
  • Consider the recent CV outcomes data from pivotal trials of antihyperglycemics when making treatment decisions for patients with poor glycemic control and established CV disease
  • Weigh real-world evidence for CV risk reduction of antihyperglycemics in patients with varying degrees of CV risk to help determine therapy selection in the setting of low to medium CV risk

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Zachary T. Bloomgarden, MD, MACE

Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Zachary T. Bloomgarden, MD, MACE, has disclosed that he has received consulting fees from AstraZeneca, Intarcia, Johnson & Johnson, Merck, Novartis, and Sanofi; has served on speaker bureaus for AstraZeneca, Johnson & Johnson, and Merck; and has ownership interest in Allergan, Novartis, Pfizer, and Zimmer Biomet.


Mikhail N. Kosiborod, MD

Professor of Medicine
Kansas City School of Medicine
University of Missouri
Consulting Cardiologist
Division of Cardiovascular Research
Department of Cardiology
Saint Luke's Mid America Heart Institute
Kansas City, Missouri

Mikhail N. Kosiborod, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eisai, GlaxoSmithKline, Glytec, Intarcia, Janssen, Merck, Novartis, Novo Nordisk, and Sanofi and funds for research support from AstraZeneca and Boehringer Ingelheim.
Pamela Kushner, MD, FAAFP

Clinical Professor
University of California Irvine Medical Center
Irvine, California
Kushner Wellness
Los Alamitos, California

Pamela Kushner, MD, FAAFP, has disclosed that she has received consulting fees from AstraZeneca, GlaxoSmithKline, and Janssen and has served on speaker bureaus for AstraZeneca, Janssen, and Lilly.


Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for endocrinologists, internists, primary care physicians, physician assistants, nurse practitioners, nurses, and other healthcare providers who care for patients with T2DM and CV risk factors.


The goal of this activity is to improve participants’ competence in applying treatment strategies that leverage new and emerging antihyperglycemic therapies in the management of patients with T2DM and elevated CV risk.

Physicians Continuing Education

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 20, 2018, through July 19, 2019:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Hyperglycemia can be a deadly complication for anyone with diabetes, but there are tools that can reduce this risk including GLP-1 medications. Learn more today.

Released: July 9, 2020

CME commentary: GLP-1 receptor agonists to prevent major cardiovascular adverse events (MACE) in type 2 diabetes (T2D), cardiovascular disease (CVD)

Anne Peters, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: June 8, 2020 Expired: June 7, 2021

CCO downloadable PDF: Evidence and expert answers on continuous glucose monitoring (CGM)

Vivian A. Fonseca, MD, FRCP
Program Director
Kushner_Pamela_32x32 Pamela Kushner, MD, FAAFP
Released: April 22, 2020

CCO downloadable PDF: benefits of continuous glucose monitoring; CGM tips for patients & providers from certified diabetes educator

person default Carla Cox, PhD, RD, FAADE Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDE Released: April 7, 2020
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?